Citigroup Forecasts Strong Price Appreciation for Alpha Tau Medical (NASDAQ:DRTS) Stock

Alpha Tau Medical (NASDAQ:DRTS) had its target price boosted by analysts at Citigroup from $7.00 to $9.00 in a report released on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Citigroup’s price objective indicates a potential upside of 29.12% from the stock’s previous close.

Several other equities research analysts have also weighed in on DRTS. HC Wainwright reiterated a “buy” rating and set a $12.00 price objective on shares of Alpha Tau Medical in a research note on Tuesday. Piper Sandler restated a “neutral” rating and issued a $5.00 target price on shares of Alpha Tau Medical in a research note on Wednesday, March 4th. Zacks Research raised Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 17th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Alpha Tau Medical in a research report on Wednesday, January 21st. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $8.67.

Alpha Tau Medical Price Performance

DRTS opened at $6.97 on Wednesday. Alpha Tau Medical has a 12-month low of $2.30 and a 12-month high of $8.60. The stock has a market capitalization of $591.20 million, a PE ratio of -13.15 and a beta of 1.02. The firm’s fifty day moving average price is $7.05 and its 200 day moving average price is $5.13.

Alpha Tau Medical (NASDAQ:DRTS) last released its earnings results on Wednesday, March 11th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). On average, equities research analysts forecast that Alpha Tau Medical will post -0.45 earnings per share for the current fiscal year.

Institutional Trading of Alpha Tau Medical

Several hedge funds have recently bought and sold shares of the company. Envestnet Asset Management Inc. bought a new position in Alpha Tau Medical in the 3rd quarter worth about $62,000. Levin Capital Strategies L.P. raised its holdings in shares of Alpha Tau Medical by 6.3% during the third quarter. Levin Capital Strategies L.P. now owns 204,714 shares of the company’s stock valued at $923,000 after buying an additional 12,200 shares during the last quarter. Bank of America Corp DE boosted its position in shares of Alpha Tau Medical by 2,779.1% during the third quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock worth $101,000 after buying an additional 21,677 shares during the period. Millennium Management LLC acquired a new position in shares of Alpha Tau Medical during the third quarter worth approximately $170,000. Finally, Mariner LLC grew its holdings in Alpha Tau Medical by 185.8% in the 3rd quarter. Mariner LLC now owns 123,250 shares of the company’s stock worth $556,000 after buying an additional 80,129 shares in the last quarter. 2.65% of the stock is currently owned by institutional investors.

Key Alpha Tau Medical News

Here are the key news stories impacting Alpha Tau Medical this week:

• Positive Sentiment: Citigroup raised its price target on DRTS from $7.00 to $9.00 and maintained a buy view, providing upward valuation pressure and a visible analyst-backed upside case. Citigroup raises price target to $9
• Positive Sentiment: HC Wainwright continues to carry a “Buy” rating and a $12.00 price target on DRTS, supporting longer-term bullish analyst sentiment despite other revisions. Alpha Tau Medical Earns Buy Rating from HC Wainwright
• Neutral Sentiment: Short-interest reports show zero shares shorted for mid-March (days-to-cover 0.0), which looks like a data/reporting anomaly and is unlikely to be a meaningful driver absent corrected figures.
• Negative Sentiment: HC Wainwright cut quarterly and full-year EPS forecasts for FY2026 (now forecasting ~($0.53) FY2026 vs. prior ($0.49)), trimming near-term profitability expectations — a clear negative for short-term sentiment despite the maintained buy rating.
• Negative Sentiment: Alpha Tau reported a recent quarterly EPS miss (reported ($0.14) vs. consensus ($0.13)), which likely weighs on investor confidence and amplifies sensitivity to the downward EPS revisions mentioned above.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.